Post on 08-Jan-2016
description
www.OncologyEducation.ca
International multicenter randomized phase III study of 1st line erlotinib followed by 2nd line cisplatin + gemcitabine vs. 1st line cisplatin + gemcitabine
followed by 2nd line erlotinib in advanced NSCLC. The TORCH trial
Authors: C.Gridelli1, F.Ciardiello2, R.Feld3, C.Butts4, V.Gebbia5, G.Genestreti6, A.Favaretto7, R.Wierzbicki8, C.Gallo2, F. Perrone9 on behalf of the TORCH Investigators
Reviewed by: Dr. Charles ButtsDate posted: ASCO 2010 Updates – June 15, 2010
www.OncologyEducation.ca
Thank you for downloading this update. Please feel free to use it for educational purposes.
Please acknowledge OncologyEducation.ca and Dr. Butts when using these slides.
www.OncologyEducation.ca
R
Treatment A:
First line Cisplatin + gemcitabine Followed by second line erlotinib at progression
Treatment B:
First line erlotinib followed by Cisplatin + Gemcitabine at progression
NSCLCNo prior chemo
Stage IIIB/IVPS 0,1
www.OncologyEducation.ca
Baseline characteristics (1)
Standard (n=380)
Experimental (n=380)
Country Italy 306 (81%) 306 (81%)
Canada 74 (19%) 74 (19%)
Gender Male 252 (66%) 252 (66%)
Female 128 (34%) 128 (34%)
Age <70 years 361 (95%) 361 (95%)
70 years 19 (5%) 19 (5%)
Median (range) 62 (34-81) 63 (27-79)
Ethnicity East-Asian 12 (3%) 12 (3%)
Other 368 (97%) 368 (97%)
Smoking status Never 79 (21%) 78 (21%)
Former, current smoker 301 (79%) 302 (79%)
www.OncologyEducation.ca
Baseline characteristics (2)
Standard (n=380)
Experimental (n=380)
ECOG PS 0 185 (49%) 197 (52%)
1 195 (51%) 183 (48%)
Stage IIIB 36 (10%) 46 (12%)
IV 344 (90%) 334 (88%)
Histology Adenocarcinoma, BAC 212 (56%) 210 (55%)
Other 168 (44%) 170 (45%)
www.OncologyEducation.ca
RESULTS
Chemo then Erlotinib
Erlotinib then Chemo
p-value
Response Rate (%)
32 % (28% then 7%)
18% (10% then 10%)
.0001
PFS first line (median,
mos) 5.7 m 2.2 m
OS
(median, mos)
12 m 8.5 m 0.002
www.OncologyEducation.ca
STUDY COMMENTARY
• This trial was designed prior to the IPASS results becoming available.
• Patient population was similar to Canadian population with majority being male, 3% Asian, and 20% never smokers
• In an unselected population of Western patients with advanced NSCLC, the standard approach with chemo first followed by erlotinib second is superior to the reverse.
• First line erlotinib results in lower response rates, shorter PFS and shorter OS in this population.
• Overall, severe toxicities were no different.
www.OncologyEducation.ca
BOTTOM LINE FOR CANADIAN MEDICAL ONCOLOGISTS
• Platinum based doublet chemotherapy remains standard first line therapy for unselected patients with advanced NSCLC.
• These results compliment and enforce the results of the IPASS trial.
• Patients with advanced NSCLC should not receive first line RGFR TKI without EGFR mutation status being tested.